Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Stock Information for Portage Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.